DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in PD-1 Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ PD-1 Non-Small Cell Lung Cancer Pipeline Outlook
Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report
- In October 2024:- BioAtla Inc.- A Phase 2 Study of BA3011 Alone and in Combination with PD-1 Inhibitor in Adult Patients with Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor. This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).
- In October 2024:- Incyte Corporation- A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304). The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
- In October 2024:- OncoC4 Inc.-The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once every 21 days, for up to 17 cycles in approximately one year.
- In October 2024:- Merck- A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer. The goal of this study is to learn if people who receive vibostolimab and pembrolizumab live longer overall and without the cancer getting worse than people who receive pembrolizumab alone.
- In October 2024:- Elpiscience (Suzhou) Biopharma, Ltd.- An Open-label, Multicenter, Single-arm Phase 2 Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer. The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
- DelveInsight’s PD-1 Non-Small Cell Lung Cancer pipeline report depicts a robust space with 25+ Renal Cancer companies working to develop 30+ pipeline therapies for PD-1 Non-Small Cell Lung Cancer treatment.
- The leading PD-1 Non-Small Cell Lung Cancer Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, and others.
- Promising PD-1 Non-Small Cell Lung Cancer Therapies such as AZD2936, Pembrolizumab, Gotistobart, Docetaxel, PF-06801591, Durvalumab, AZD9150, AZD6738, REGN2810, and others.
Stay informed about the cutting-edge advancements in PD-1 Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ PD-1 Non-Small Cell Lung Cancer Clinical Trials Assessment
PD-1 Non-Small Cell Lung Cancer Emerging Drugs Profile
- Zimberelimab: Arcus Biosciences
Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin’s lymphoma. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. The most advanced study with zimberelimab is in Phase III development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic.
- PM8002: Biotheus
PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations. PM8002 had demonstrated a positive safety profile and encouraging antitumor activity presumably through reduced systemic toxicity by enriching anti-VEGF activity into the tumor microenvironment at ASCO Annual Meeting and ESMO Congress 2023. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of NSCLC.
- RPH075: R-Pharm
R-Pharm’s pembrolizumab biosimilar, known as RPH 075, is a monoclonal antibody classified under antineoplastics, antivirals, and immunotherapies, specifically tumor-agnostic therapies. This biosimilar mimics the action of the originator drug, pembrolizumab, by targeting and antagonizing the programmed cell death 1 (PD-1) receptor on T lymphocytes. By blocking the interaction between PD-1 and its ligands, RPH 075 enhances T-cell mediated immune responses against cancer cells, promoting antibody-dependent cell cytotoxicity and providing a potent means to counteract tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of NSCLC.
Learn more about PD-1 Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking PD-1 Non-Small Cell Lung Cancer Research and development projects @ PD-1 Non-Small Cell Lung Cancer Unmet Needs
PD-1 Non-Small Cell Lung Cancer Companies
Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, and others.
PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
PD-1 Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Discover the latest advancements in PD-1 Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report
- Coverage- Global
- PD-1 Non-Small Cell Lung Cancer Companies- Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, and others.
- PD-1 Non-Small Cell Lung Cancer Therapies- AZD2936, Pembrolizumab, Gotistobart, Docetaxel, PF-06801591, Durvalumab, AZD9150, AZD6738, REGN2810, and others
- PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of PD-1 Non-Small Cell Lung Cancer Pipeline on our website @ PD-1 Non-Small Cell Lung Cancer Drugs and Companies
Table of Content
- Introduction
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC): Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- PD-1 Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Zimberelimab: Arcus Biosciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- RPH075: R-Pharm
- Preclinical Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Collaborations Assessment- Licensing / Partnering / Funding
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Unmet Needs
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Market Drivers and Barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers